GILD · NASDAQ
Gilead Sciences (GILD) Stock Price & Fundamentals
Gilead Sciences (GILD) closed at $1,159.85 on Oct 9, 2026, down 1.08% from the previous close of $1,172.51.
Share price, past year
1Y +8.76%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,159.85 |
| Sep 30, 2026 | $1,147.64 |
| Aug 31, 2026 | $1,281.74 |
| Jul 31, 2026 | $1,300.35 |
| Jun 30, 2026 | $1,207.16 |
| May 29, 2026 | $1,227.31 |
| Apr 30, 2026 | $1,185.79 |
| Mar 31, 2026 | $1,236.42 |
| Feb 27, 2026 | $1,270.66 |
| Jan 30, 2026 | $1,287.19 |
| Dec 31, 2025 | $1,243.21 |
| Nov 28, 2025 | $1,141.29 |
| Oct 31, 2025 | $1,148.06 |
Key statistics
- Market cap
- $1.44T
- P/E (TTM)
- —
- EPS (TTM)
- −$2.66
- Revenue (TTM)
- $30.46B
- Net income (TTM)
- −$3.24B
- Shares outstanding
- 1.2B
- Dividend yield
- 0.28%
- 52-week range
- $1,066.41 – $1,342.36
Gilead Sciences's market cap is $1.44T, based on a share price of $1,159.85 and 1.2B shares outstanding as of Jun 30, 2026.
Financials
Gilead Sciences reported revenue of $29.44B for fiscal 2025, up 2.40% from fiscal 2024.
Gilead Sciences earned net income of $8.51B in fiscal 2025, a net margin of 28.9%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $29.44B | +2.4% | $8.51B | 28.9% | $6.78 | $9.46B |
| FY2024ended Dec 31, 2024 | $28.75B | +6.0% | $480.00M | 1.7% | $0.38 | $10.31B |
| FY2023ended Dec 31, 2023 | $27.12B | −0.6% | $5.67B | 20.9% | $4.50 | $7.42B |
| FY2022ended Dec 31, 2022 | $27.28B | −0.1% | $4.59B | 16.8% | $3.64 | $8.34B |
| FY2021ended Dec 31, 2021 | $27.31B | +10.6% | $6.23B | 22.8% | $4.93 | $10.81B |
| FY2020ended Dec 31, 2020 | $24.69B | +10.0% | $123.00M | 0.5% | $0.10 | $7.52B |
| FY2019ended Dec 31, 2019 | $22.45B | +1.5% | $5.39B | 24.0% | $4.22 | $8.32B |
| FY2018ended Dec 31, 2018 | $22.13B | −15.2% | $5.46B | 24.7% | $4.17 | $7.48B |
| FY2017ended Dec 31, 2017 | $26.11B | −14.1% | $4.63B | 17.7% | $3.51 | — |
| FY2016ended Dec 31, 2016 | $30.39B | — | $13.50B | 44.4% | $9.94 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $7.80B | −$10.50B | −$8.45 |
| Q1 FY2026ended Mar 31, 2026 | $6.96B | $2.02B | $1.61 |
| Q4 FY2025ended Dec 31, 2025 | $7.93B | $2.18B | $1.75 |
| Q3 FY2025ended Sep 30, 2025 | $7.77B | $3.05B | $2.43 |
| Q2 FY2025ended Jun 30, 2025 | $7.08B | $1.96B | $1.56 |
| Q1 FY2025ended Mar 31, 2025 | $6.67B | $1.32B | $1.04 |
| Q4 FY2024ended Dec 31, 2024 | $7.57B | $1.78B | $1.43 |
| Q3 FY2024ended Sep 30, 2024 | $7.55B | $1.25B | $1.00 |
Company profile
- Name
- Gilead Sciences, Inc.
- Ticker
- GILD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 333 Lakeside Dr, Foster City, CA 94404
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000882095
Recent SEC filings
- Aug 6, 2026
- Aug 4, 2026
- May 20, 2026
- May 7, 2026
- May 7, 2026
- May 4, 2026
- Apr 28, 2026
- Feb 24, 2026
Frequently asked questions
What is Gilead Sciences's stock price?
Gilead Sciences (GILD) closed at $1,159.85 on Oct 9, 2026, down 1.08% from the previous close of $1,172.51.
What is Gilead Sciences's market cap?
Gilead Sciences's market cap is $1.44T, based on a share price of $1,159.85 and 1.2B shares outstanding as of Jun 30, 2026.
How much revenue does Gilead Sciences make?
Gilead Sciences reported revenue of $29.44B for fiscal 2025, up 2.40% from fiscal 2024.
Does Gilead Sciences pay a dividend?
Yes. Gilead Sciences declared $3.22 per share in dividends over the last four quarters, a yield of 0.28%.
Sources and methodology
Fundamentals come from Gilead Sciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures